Neurology:DRAGON评分方法有助医生决定对中风者采取何种措施

2012-02-11 MedSci MedSci原创

阿替普酶属机体抗凝血因子,能结合到血纤维蛋白上,激活纤维蛋白酶原,使其转化成血纤维蛋白酶,继而溶解血纤维蛋白,使血栓得以溶解。临床上主要用于治疗急性心肌梗塞。 近日,Neurology杂志上的刊登的一项表明:研究人员成功开发的一种新的评分方法可以帮助临床医生快速判断阿替普酶对哪种类型的中风症有效,这种名叫DRAGON的简单、快速且免费的评分方法具有86%的准确率。 共有1,319名接受阿替普酶

阿替普酶属机体抗凝血因子,能结合到血纤维蛋白上,激活纤维蛋白酶原,使其转化成血纤维蛋白酶,继而溶解血纤维蛋白,使血栓得以溶解。临床上主要用于治疗急性心肌梗塞。

近日,Neurology杂志上的刊登的一项表明:研究人员成功开发的一种新的评分方法可以帮助临床医生快速判断阿替普酶对哪种类型的中风症有效,这种名叫DRAGON的简单、快速且免费的评分方法具有86%的准确率。

共有1,319名接受阿替普酶治疗的缺血性中风患者参与了该项研究,他们的平均年龄在69岁左右。研究者根据参与人员的年龄、血糖水平、中风症状开始的时间以及中风程度等因素,给这些人以0至10的打分。

得分越高的患者在接受治疗三个月后,出现死亡或者长期卧床、大小便失禁等情况的可能性更大。而得分在为0到2之间的患者,96%的人在接受治疗三个月后并不会出现上述症状。

该项研究的主要负责人--芬兰赫尔辛基大学中心医院的Daniel Strbian博士表示:这种快速的评分方式可以帮助医生、病患及病人家属更快作出选择,在最短时间内决定最有效的治疗手段。

Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis

D. Strbian, MD, PhD, T. Sairanen, MD, PhD, A. Meretoja, MD, MSc (Stroke Med), J. Pitkniemi, PhD (Stat), J. Putaala, MD, PhD,et al.

Objectives: To assess the impact of symptomatic intracerebral hemorrhage (sICH) on outcome of thrombolysis-treated ischemic stroke patients, as additional to recognized prognosticators.

Methods: The study cohort included 985 ischemic stroke patients treated with IV thrombolysis at the Helsinki University Central Hospital (1995–2008). In a multivariable model adjusted for baseline stroke severity, age, onset-to-treatment time, baseline glucose, hyperdense cerebral artery sign, and early infarct signs on baseline imaging, and prior modified Rankin Scale (mRS), we calculated risk ratios (RRs) of patients with sICH (separately per Safe Implementation of Thrombolysis in Stroke [SITS] –Monitoring Study, European Cooperative Acute Stroke Study II [ECASS-II], and National Institute of Neurological Disorders and Stroke [NINDS] definitions) for poor 3-month outcome (mRS 3–6) and mortality. Receiver operating characteristic (ROC) curve and integrated discrimination improvement (IDI) evaluated impact of sICH on outcome. Internal cross-validation of the model was done with bootstrap statistics.

Results: The frequency of sICH was 2.1% (SITS), 7.0% (ECASS-II), and 9.4% (NINDS). RRs for poor and fatal outcome, respectively, were 1.7 and 4.8 (SITS), 1.6 and 3.8 (ECASS-II), and 1.6 and 3.4 (NINDS). In IDI analyses, sICH improved prediction model for 3-month mRS of 3–6 and 4–6, respectively, by 1.4% and 3.0% (SITS), 4.0% and 5.9% (ECASS-II), and 4.7% and 6.1% (NINDS). In case of 3-month mRS 5–6 and mortality, it was 6.1% and 5.3% (SITS), 11.3% and 9.3% (ECASS-II), and 10.3% and 8.0% (NINDS). ROC analysis revealed similar results.

Conclusions: Patients with sICH have increased risk of poor and fatal outcome. Compared with recognized stroke prognosticators, contribution of sICH is smaller. Definition-wise, ECASS-II- and NINDS-based sICH contribute relatively more; ECASS-II has the largest contribution to worst outcomes.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=37414, encodeId=9bb43e414f1, content=This shows real exritpese. Thanks for the answer., beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mohamed, createdTime=Sun Sep 27 07:56:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085608, encodeId=5cc520856086d, content=<a href='/topic/show?id=f67291500ad' target=_blank style='color:#2F92EE;'>#评分方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91500, encryptionId=f67291500ad, topicName=评分方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 28 07:39:00 CST 2012, time=2012-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999189, encodeId=6f17199918939, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 01 17:39:00 CST 2012, time=2012-07-01, status=1, ipAttribution=)]
    2015-09-27 mohamed

    This shows real exritpese. Thanks for the answer.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=37414, encodeId=9bb43e414f1, content=This shows real exritpese. Thanks for the answer., beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mohamed, createdTime=Sun Sep 27 07:56:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085608, encodeId=5cc520856086d, content=<a href='/topic/show?id=f67291500ad' target=_blank style='color:#2F92EE;'>#评分方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91500, encryptionId=f67291500ad, topicName=评分方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 28 07:39:00 CST 2012, time=2012-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999189, encodeId=6f17199918939, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 01 17:39:00 CST 2012, time=2012-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=37414, encodeId=9bb43e414f1, content=This shows real exritpese. Thanks for the answer., beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mohamed, createdTime=Sun Sep 27 07:56:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085608, encodeId=5cc520856086d, content=<a href='/topic/show?id=f67291500ad' target=_blank style='color:#2F92EE;'>#评分方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91500, encryptionId=f67291500ad, topicName=评分方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 28 07:39:00 CST 2012, time=2012-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999189, encodeId=6f17199918939, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 01 17:39:00 CST 2012, time=2012-07-01, status=1, ipAttribution=)]
    2012-07-01 yinhl1978